This will be fuelled by disease-modifying therapies.
This will be fuelled by disease-modifying therapies. The Alzheimer’s disease (AD) market across the eight major markets (8MM) is forecast to grow to $14.7b by 2033, driven by the entry of expensive disease-modifying therapies (DMTs). According to GlobalData, an ageing global population and the launch of novel symptomatic therapies to treat agitation and psychosis are also contributing to market growth.
The report noted that DMTs are expected to dominate the market, contributing 63.7% of total sales by 2033. However, integrating DMTs into clinical practice to make them widely available for…
Read the full report on Healthcare Asia Magazine
Story file
- Section
- Health
- First reported by
- Healthcare Asia Magazine
- Reporter
- staff reporter
- Published
- Wednesday, 14 October 2026, 7:18 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Healthcare Asia Magazine with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.
